Lipid droplets (LDs) are intracellular organelles that store neutral lipids within cells. Over the last two decades there has been a dramatic growth in our understanding of LD biology and, in parallel, our understanding of the role of LDs in health and disease. In its simplest form, the LD regulates the storage and hydrolysis of neutral lipids, including triacylglycerol and/or cholesterol esters. It is becoming increasingly evident that alterations in the regulation of LD physiology and metabolism influence the risk of developing metabolic diseases such as diabetes. In this review we provide an update on the role of LD-associated proteins and LDs in metabolic disease.
Lipid droplets (LDs) are intracellular organelles that store neutral lipids within cells. Over the last two decades there has been a dramatic growth in our understanding of LD biology and, in parallel, our understanding of the role of LDs in health and disease. In its simplest form, the LD regulates the storage and hydrolysis of neutral lipids, including triacylglycerol and/or cholesterol esters. It is becoming increasingly evident that alterations in the regulation of LD physiology and metabolism influence the risk of developing metabolic diseases such as diabetes. In this review we provide an update on the role of LD-associated proteins and LDs in metabolic disease.

Overview of lipid droplets
Lipid droplets (LDs) are intracellular organelles that store neutral lipids within cells. Over the last two decades there has been a dramatic growth in our understanding of LD biology and, in parallel, our understanding of the role they play in health and disease. LDs regulate the storage and hydrolysis of neutral lipids, including triacylglycerol (TAG) and/or cholesterol esters. For example, adipocytes, the major reservoir of TAG in the body, store their TAG within LDs, and TAG storage in adipocytes is increased in obese animals and humans. The rates of adipocyte lipolysis in many obese individuals are constitutively increased, resulting in elevated levels of circulating fatty acids, which may be stored as TAG in LDs within skeletal muscle and liver. Both local and circulating free fatty acids are thought to be important etiologic agents in the development of insulin resistance, hyperlipidemia, inflammation, and hepatic steatosis (1–3). In this article, we will briefly review the basic characteristics of LDs and then focus on our present knowledge of the current view of the role of LDs in metabolic disease.

Cells have developed the capacity to store fatty acids as neutral lipids within LDs for several reasons. An important role of LDs in adipocytes is to store fatty acids as TAG to serve as a reservoir of energetic substrates that can be released when food is scarce. Adipocytes, fly cells, and leukocytes have revealed the existence of many LD-associated proteins, including specific marker proteins, structural proteins, enzymes involved in various aspects of cholesterol and fatty acid metabolism, and proteins that function as regulators of membrane trafficking (20–32).

A critical catalyst in our understanding of LD biology came with the identification of the first LD-associated protein, perilipin 1 (PLIN1). PLIN1 was discovered during an experiment in which adipocytes were incubated with radiolabeled 32P to label the cellular pool of ATP. When the adipocytes were treated with catecholamines to activate cAMP and cAMP-dependent PKA, autoradiogram analysis showed a protein that contained more than 95% of all the 32P (33). This protein was named “perilipin” because both...
cell fractionation and immunohistochemical studies demonstrated that it localized, in the absence and presence of PKA activation, specifically at the surface of LDs. Tissue surveys revealed that PLIN1 is most highly expressed in adipocytes and to a lesser extent in steroiogenic tissues (34). Cloning of the cDNA for Plin1 identified a major isoform, perilipin A (35), although other isoforms are expressed at lower levels (35, 36). In silico analysis revealed four additional LD-associated proteins with homology to the N-terminal region of Plin1: ADRP (also referred to as Plin2), TIP47 (Plin3), S3-12 (Plin4), and OXPAT (Plin5). These constitute the perilipin/ADRP/TIP47 (PAT) family, which is conserved in a variety of organisms, from slime mold to mammals (36, 37). In this review we will focus on Plin1, which is the most abundant and most thoroughly studied PAT protein in adipocytes (38–42), and on PLIN2 because of its patatin protein domain, and bound to the G0S2 protein, which inhibits its hydrolytic activity (48). The protein CGI-58 is associated with the LD surface, perhaps because of its patatin protein domain, and bound to the G0S2 protein, which inhibits its hydrolytic activity (48). The protein CGI-58 is associated with the LD under basal conditions and can associate with ATGL and increase its catalytic activity by up to 20-fold (49). While a small amount of HSL may be associated with the LD in the absence of PKA activation, HSL is predominately located in the absence of PKA activation, Plin1 appears to reduce lipolysis by up to 20-fold (49). When a small amount of HSL may be associated with the LD in the absence of PKA activation, HSL is predominately located in the cytoplasm (50, 51). Monacyglycerol lipase is thought to be constitutively activated in the absence of any phosphorylation. In the absence of PKA activation, Plin1 appears to reduce lipolysis by binding and sequestering CGI-58 and, possibly, a small amount of HSL on the droplet (51–53). Basal levels of lipolysis are predominately due to constitutive actions of ATGL (54, 55). PKA activation phosphorylates Plin1, resulting in the release of CGI-58, which then binds to and increases ATGL hydrolytic activity on the droplet (52, 53). Thus, a reduction in Plin1 would result in release of CGI-58, thereby allowing it to bind ATGL, increasing the catalytic activity of ATGL and accelerating the first step of lipolysis. Additionally, PKA phosphorylation of HSL causes the protein to translocate to the LD surface, where it binds hyperphosphorylated Plin1 and preferentially hydrolyzes diaacylglycerol. There are likely other potential mechanisms and factors that regulate lipolysis. In this review we will discuss how several of these proteins are dysregulated in human disease.

Like the PAT proteins, the CIDE family of proteins also associates with and regulates LD physiology. The CIDE family consists of three proteins: Cidea, Cideb, and Cidec (also referred to as fat-specific protein 27 [FSP27]). The N-terminal region of the CIDE proteins shares homology with the two-subunit proteins of DNA fragmentation factor, which is involved in apoptosis (56). Additionally, the CIDE proteins have regions of homology with PLIN1, including a hydrophobic domain thought to be important for binding to the phospholipid monolayer of the droplet (57). Cidec was the first of this family to be identified as an LD-associated protein (58, 59). Subsequently, similar to PAT proteins, ectopic expression of Cide proteins promotes LD formation and reduces TAG hydrolysis (57, 60, 61). Relevant to their homology to proteins associated with apoptosis, ectopic expression of CIDE members enhances rates of apoptosis. However, when CIDE-expressing cells are incubated with oleic acid to promote TAG storage and LD formation, the rates of apoptosis are significantly reduced, presumably because sequestration of the Cide proteins on the droplets blocks their proapoptotic function (60). Cidea in lean mice is expressed predominately in brown adipose tissue (BAT), but not in white adipose tissue (WAT) (62). Cidec in mice is predominately expressed in WAT, but has also been found in BAT (62–64) and lipid-laden hepatocytes (6, 56). In humans, the expression pattern is slightly different, with both CIDEC and CIDEA highly expressed in white adipocytes (57, 65).

Role of LD proteins in obesity-associated insulin resistance, diabetes, and lipodystrophic diabetes

LD proteins in lipoatrophic diabetes. Plin1 and members of the PAT family are critical regulators of lipid metabolism. In obesity, insulin resistance has been linked to increased rates of adipocyte lipolysis (1, 3, 66, 67) and increased expression of cytokines such as TNF-α. One of the first clues in elucidating Plin1 function was the observation that TNF-α reduces Plin1 mRNA and protein expression while concomitantly increasing basal lipolysis (68). Constitutive overexpression of Plin1 in cultured adipocytes blocks the ability of TNF-α to increase lipolysis, confirming a role for PLIN1 expression in regulating basal or constitutive lipolysis (69). Critical insights into the role of PLIN1 in systemic metabolism were demonstrated when two separate laboratories independently generated lines of Plin1-null mice; both groups observed that the mice were lean and developed systemic insulin resistance as they got older (70, 71). Studies comparing lipolysis in Plin1-null and wild-type mice revealed that Plin1-null adipocytes had increased rates of constitutive (unstimulated) lipolysis and reduced catecholamine-stimulated lipolysis (70). In these cells, Plin2 replaced Plin1 protein on the LD, which suggests that Plin2 is less efficacious in blocking basal adipocyte lipolysis (70, 72). Nelfinavir, an anti-HIV drug, has been reported to promote lipodystrophy in humans (73), and we demonstrated that it specifically enhanced Plin1 degradation by a lysosomal pathway in mouse adipocytes, resulting in increased rates of constitutive basal lipolysis. These data demonstrate that Plin1 protein enhances catecholamine-stimulated lipolysis and, importantly, that a reduction in Plin1 protein expression is associated with increased constitutive lipolysis, which can promote systemic insulin resistance. Recently, three individuals were reported to have one of two different heterozygous missense mutations in PLIN1, which altered the amino acids in the carboxy terminus of the protein. When ectopically expressed in cells, these mutant proteins were found to have reduced ability to block TAG hydrolysis, leading to increased rates of constitutive lipolysis as compared with wild-type PLIN1 (74). These subjects had partial lipodystrophy, with loss of adipose tissue in their femorogluteal region and lower limbs, along with Cushingoid or acromegaloid features, insulin-resistant diabetes, hypertriglyceridemia and hepatic steatosis.
Similar to Plin1, TNF-α treatment of mouse adipocytes reduces Cidec expression, and siRNA knockdown of Cidec increases rates of basal constitutive lipolysis, whereas overexpression of Cidec blocks the effect of TNF-α on lipolysis (57–60, 65, 75, 76). Two separate laboratories generated Cidec-knockout mice (63, 64). Cidec-knockout mice have features similar to those of Plin1-null mice, such as reduced fat mass and increased lipolysis (63). The knockout animals have increased energy expenditure and are protected against the development of genetic or diet-induced obesity (70, 71). Basal lipolysis is increased in isolated white adipocytes from Cidec-null mice, and catecholamine-stimulated lipolysis is reduced (63). However, unlike Plin1-null mice, Cidec-null mice are protected against the development of diet-induced insulin resistance. One human patient has been described as having a homozygous nonsense mutation in the CIDEC gene that resulted in a truncated protein that was unable to associate with LDs (77). This patient had partial lipodystrophy with absence of femorogluteal and lower-limb adipose tissue, along with insulin-resistant diabetes, hypertriglyceridemia, and hepatic steatosis (see Figure 1). The mechanism by which Cidec blocks basal lipolysis remains poorly understood and is a goal of future research studies. Thus, loss of PLIN1 or CIDEC expression in humans, unlike mice, results in ectopic lipid accumulation, dyslipidemia, and diabetes.

Besides the increase in adipocyte lipolysis which reduces TAG content in adipocytes, the constitutive lipolysis induced by a reduction in either Plin1 or Cidec also reduces fat mass by activating fat oxidation pathways. For example, fatty acids from lipolysis can directly activate transcription factors such as PPARs to promote fat oxidation (78, 79). Additionally, lipolysis in white adipocytes can activate AMP-activated protein kinase, which also promotes fat oxidation and reduces lipogenesis (80). In both Cidec- and Plin1-null mice, oxidative gene expression is increased in WAT (63, 64, 81, 82). Furthermore, in Cidec-null mice, uncoupling protein 1 (UCP1) expression is increased in WAT, endowing it with characteristics of brown adipocytes such as multilocular LDs and enhanced thermogenesis (64). Thus, with reduced expression of LD proteins and increased lipolysis, fatty acids can promote fat oxidation. However, this compensatory pathway is not sufficient to prevent the detrimental release of fatty acids and subsequent development of insulin resistance, at least in Plin1-null mice. Potentially, differences in rates of constitutive lipolysis and fat oxidation in adipocytes may at least in part explain the differential susceptibility of Plin1- and FSP27/Cidec-null mice to insulin resistance. Of potential relevance is our observation that overexpressing human or mouse Plin1 in female mice protects against the development of obesity and obesity-associated insulin resistance while increasing expression of oxidative genes in adipose tissue (83, 84). Overexpression of Plin1 potently reduces expression of FSP27 in adipocytes, which may partly explain the protection against obesity and insulin resistance. In summary, a significant reduction in LD proteins may promote both lipolysis and oxidative metabolism, providing another mechanism to reduce adipose mass.

While BAT has recently emerged as being present in humans, its role in regulating adult metabolism is unclear (85). In mice, BAT contributes to the regulation of body adiposity and thermogenesis. Similar to WAT, brown adipocytes store TAG and, in response
to locally released norepinephrine, undergo PKA-activated lipolysis. However, brown adipocytes express UCPI, which uncouples the generation of ATP from fat oxidation, resulting in the generation of heat. Fatty acids released by lipolysis directly activate UCPI. Ablation of the Cidea gene in mice, which is predominantly expressed in BAT in mice, results in increased BAT lipolysis, temperature, metabolic rate, and a reduction in respiratory exchange ratio consistent with increased fat oxidation (62). Additionally, the presence of Cidea promotes degradation of the AMPKβ subunit (86), reducing AMPK activation, which may also contribute to reduced oxidative metabolism and protection against diet-induced obesity. Brown adipocytes also express Plin1. In recent studies using lines of transgenic and Plin1-knockout mice, we demonstrated that the mutation of the six consensus PKA sites of Plin1 from serine to alanine blocked catecholamine-stimulated lipolysis (96), reducing AMPK activation, which may also contribute to reduced adipocyte lipolysis (108–109). Genes influence body weight and the risk of metabolic disease. Interestingly, one PLIN1 polymorphism was found to be associated with reduced PLIN1 expression and increased rates of basal and stimulated adipocyte lipolysis (95). Consistent with the increased rates of lipolysis, humans with this polymorphism tend to have reduced body weight and body fat mass (106, 110). PLIN1 polymorphisms have also been suggested to affect the ability to lose weight on a diet (101, 103), as well as the metabolic response to exercise (111). More work is needed to confirm and extend these observations among different human populations.

Role of LDs in non-alcoholic fatty liver disease and nonalcoholic steatohepatitis

In obese humans, nonalcoholic fatty liver disease (NAFLD) is becoming more prevalent (112, 113) and can lead to nonalcoholic steatohepatitis (NASH), cirrhosis, and even cancer (114). Hepatic steatosis is often associated with resistance to the actions of insulin on hepatic gluconeogenesis, while hepatocytes remain sensitive to the lipogenic actions of insulin (115). In obesity, fatty acids released from adipocytes are an important source of fatty acids that are found as TAG within hepatic LDs (116). There are a limited number of papers that have investigated the role of LD proteins in human liver, with the greatest number focusing on the PAT proteins. In normal liver both PLIN2 and PLIN3 have been found to be associated with LDs (46). However, with the development of hepatic steatosis, PLIN1 protein is found localized to hepatocyte LDs (46). Consistent with this histologic observation, two separate studies, which used microarray analysis to determine the expression pattern of proteins in NAFLD, revealed PLIN1 as one of the most prominent upregulated genes (117, 118). Interestingly, in steatotic hepatocytes, the pattern of PLIN1, -2, and -3 proteins differ depending upon the size of the LDs and their intracellular localization (46). In a second study, the association of PLIN1 and PLIN2 with LDs were observed in subjects with both NAFLD and NASH (119). PLIN1 tended to be associated with larger LDs, while expression of PLIN2 was more correlated with the presence of ballooned hepatocytes and evidence of oxidation (119). The possible significance and differing roles of PLIN1 and -2 in liver disease is an important unanswered question.

The liver contains several lipases, including ATGL, HSL, TAG lipase (120), and a related lipase called “PNPLA3” (ref. 121; Figure 2). In a genome-wide scan, mutations in PNPLA3 were associated with an increased risk of NAFLD in Hispanics and reduced risk in African Americans (121). PNPLA3 was identified as a LD protein that hydrolyzes TAG (122). More recently a missense mutation
(L148M) in PNPLA3 was associated with increased risk of developing NAFLD. Importantly, in vitro studies revealed that this mutation in PNPLA3 ablated the ability of the protein to hydrolyze TAG (122). However, it is important to note that PNPLA3-knockout mice do not develop hepatic steatosis (123), which suggests that the PNPLA3 mutants identified in humans might interfere with other proteins involved in normal hepatic LD metabolism.

While we have limited knowledge of how PLIN2 accumulation regulates the accumulation of TAG in hepatocytes of humans, most of our knowledge about the in vivo role of these LD proteins is inferred from studies in rodents. Plin2 and Plin3, but not Plin1, are generally associated with hepatic LDs of rodents. More recently we found that addition of alcohol to a high-fat diet resulted in expression of both Plin1 and -2 and hepatocyte LD (124), but the importance and mechanisms that result in Plin1 expression here are unclear. Loss of Plin2 expression in mice reduced the effect of high-fat diet–induced liver TAG accumulation (125). When the Plin2-knockout mice were crossed with ob/ob mice, the insulin resistance of the double-knockout mice improved in both the liver and skeletal muscle (126). In ob/ob/Plin2-null mice, liver fat accumulation was reduced by 25%, perhaps secondary to increased VLDL secretion. With loss of Plin2, Plin3 became associated with the LDs, while Plin5 expression was greatly increased. Knockout or knockdown of Plin2 in the liver reduces hepatic TAG levels in both genetic and diet-induced obese mice and improves hepatic insulin sensitivity (125–128). The increased insulin sensitivity in mice with reduced or ablated Plin2 might be explained by reduced hepatic diacylglycerol content (128, 129).

Previous studies had suggested that one mechanism by which Plin2 expression reduces lipid hydrolysis was that it excludes ATGL from the droplet (130). In support of this observation, overexpression of Plin2 significantly decreases TAG hydrolysis in hepatocytes, while siRNA knockdown of Plin2 or overexpression of ATGL enhances TAG hydrolysis (131). Interestingly, altering TAG hydrolysis through manipulations of Plin2 or ATGL regulates PPARα activity and target gene expression. Specifically, ATGL overexpression and Plin2 knockdown activate PPARα, whereas Plin2 overexpression inhibits PPARα activity and fat oxidation (128, 131). Plin2 ablation may reduce hepatic TAG and increase insulin sensitivity in obese mice by several mechanisms. In contrast, combined knockdown of both Plin2 and Plin3 in cultured hepatocytes exposed to fatty acids results in significantly increased insulin resistance (132). In summary, reduction of Plin2 promotes a reduction in hepatic steatosis and increases insulin sensitivity, but a reduction in both Plin2 and Plin3 causes insulin resistance.

The CIDE proteins are also expressed on hepatocyte LDs in obesity are linked to hepatic steatosis and insulin resistance. Fatty acids from the diet or adipocyte lipolysis result in accumulation of neutral lipids in LD in hepatocytes and incorporation of PLIN2, PLIN3, CIDEA, CIDEB, CIDEC, and ATGL on the LD surface. In humans, PLIN1 is also found on hepatic LDs in individuals with NAFLD and NASH. Increased fatty acid accumulation and LD formation are in general associated with increased accumulation of diacylglycerol (DAG) and inflammatory cytokines. DAG activates atypical PKC, and fatty acids and cytokines activate inflammatory signaling pathways, which cumulatively block the actions of IRS-1 and -2 and promote insulin resistance. It is possible that DAG as well as TAG accumulate in LDs. In hepatocytes, insulin resistance is marked by increased hepatic gluconeogenesis and reduced glycogen formation. Notably, mutations in the phospholipase PNPLA3 result in hepatic steatosis.

![Figure 2](http://www.jci.org)

**Figure 2**
Liver LD increases in obesity are linked to hepatic steatosis and insulin resistance. Fatty acids from the diet or adipocyte lipolysis result in accumulation of neutral lipids in LD in hepatocytes and incorporation of PLIN2, PLIN3, CIDEA, CIDEB, CIDEC, and ATGL on the LD surface. In humans, PLIN1 is also found on hepatic LDs in individuals with NAFLD and NASH. Increased fatty acid accumulation and LD formation are in general associated with increased accumulation of diacylglycerol (DAG) and inflammatory cytokines. DAG activates atypical PKC, and fatty acids and cytokines activate inflammatory signaling pathways, which cumulatively block the actions of IRS-1 and -2 and promote insulin resistance.
insulin sensitive (134). Cideb within the liver is necessary for the acquisition of TAG and apoB binding in the developing VLDL particle (61). Thus the CIDE proteins have an important but not completely understood role in hepatic LD metabolism.

LDs and skeletal muscle metabolism

Our understanding of the role of LDs in regulating metabolism in skeletal muscle is less well developed, and a function of PAT proteins in regulating insulin action in skeletal muscle of obese and diabetic individuals has not been well delineated. Studies conflict as to whether the level of PLIN2, or possibly PLIN5, is related to insulin resistance in obese, diabetic individuals (135, 136). Tissue-specific ablation of Plin2 and -5 in skeletal muscle will provide important insights into their actions. In certain states, skeletal muscle can store increased amounts of TAG in LDs, which correlates with insulin resistance (137). Intriguingly, SNARE proteins such as SNAP23 are required for both LD fusion (138) as well as membrane to the surface of the newly formed LDs (138). SNAP23 sequestration on LDs of oleic acid–treated cells was coincident with attenuated insulin-stimulated glucose transport. Moreover, consistent with these in vitro observations, more SNAP23 was localized to the non-plasma membrane pool in muscle cells of type 2 diabetics in whom intracellular lipid was increased (139).

Mutations in genes involved in LD turnover have been linked to lipid storage disease and myopathy in humans. Mutations in ATGL result in a form of neutral lipid storage disease with myopathy that is manifest by TAG accumulation in skeletal and cardiac muscle, liver, and leukocytes (140–142). Other than myopathy, metabolic manifestations have been variable, with most patients having normal glucose and lipid levels (140–142). Mutations in CGI-58 also result in neutral lipid storage disease (Chanarin-Dorfman syndrome) and are associated with ichthyosis (143, 144). Thus, there are TAG droplets observed in skin, liver, and leukocytes. No mutations have yet been described in other genes involved in LD hydrolysis, such as HSL.

One complicating issue in relating muscle TAG to insulin sensitivity is that the muscle of elite athletes contains high amounts of myocellular fat in the absence of insulin resistance (145). A possible explanation for this paradox may lie in the fact that exercise increases the expression of the enzyme DGAT1 in skeletal muscle (146). DGAT1 catalyzes the addition of a fatty acyl group to diacylglycerol to form TAG. Transgenic mice overexpressing Dgat1 in skeletal muscle are protected against the development high-fat diet–induced insulin resistance (147). These Dgat1 transgenic mice have increased TAG in skeletal muscle, but less diacylglycerol and reduced activation of the PKC isoforms that promote insulin resistance. Muscles from these transgenic mice also have increased fatty acid oxidation (148).

The observation that DGAT overexpression promotes the formation of TAG without causing insulin resistance has been replicated in other tissues besides muscle. Overexpressing DGAT in liver results in hepatic steatosis but does not cause insulin resistance (149). One line of Dgat1 transgenic mice in which Dgat1 was overexpressed in both adipocytes and macrophages or in macrophages alone was protected against diet-induced insulin resistance (150, 151). Furthermore, overexpression of Dgat1 in heart protects against cardiac lipotoxicity (152). These data underscore the importance to metabolic health of sequestering excess free fatty acids in esterified form (TAG) within LDs.

Conclusion

All cells can form and sequester neutral lipids within LDs, especially when exposed to increased levels of fatty acids. At present, it is evident that proteins in the PAT and CIDE families can facilitate the storage of fatty acids within LDs and reduce rates of hydrolysis. However, these LD-associated proteins differ in their ability to modulate lipid hydrolysis. Our appreciation of the multiple physiologic and pathophysiologic roles of LDs continues to evolve, with LDs now recognized as important regulators of atherosclerosis (153, 154), cancer (155), and viral replication (156). It is exciting that we are just beginning to appreciate the full complexity and importance of LD metabolism. Greater understanding of LD biogenesis, composition, and heterogeneity will provide new insights in understanding the role of LDs in health and disease.

Acknowledgments

This work was supported by grants from the American Diabetes Association (7-08-RA-57 to A.S. Greenberg; 7-07-JF-43 to D.G. Mashek), the USDA Agricultural Research Service (58-1950-7-707 to A.S. Greenberg), the Department of Veterans Affairs Office of Research and Development Medical Research Service (to F.B. Kraemer) and the NIH (AG028098 to F.B. Kraemer; DK082257, 1RC1ES018781, and R24DK087669 to A.S. Greenberg; DK56598 and DK59935 to R.A. Coleman; RO1-HD045962 and PO1-HD38129 to J.L. McMahan; 3P30DK046200 to V. Puri; DK074979 to M.S. Obin; and DK085008 to D.G. Mashek). The Obesity Review Series is supported in part by unrestricted educational grants from Merck & Co. and the Life Sciences Institute of the University of Michigan.

Address correspondence to: Andrew S. Greenberg, Tufts University, 711 Washington Street, Boston, Massachusetts 02111, USA. Phone: 617.556.3144; Fax: 617.556.3224; E-mail: Andrew.greenberg@tufts.edu.

11. Novikoff AB, Novikoff PM, Rosen OM, Rubin CS. Organelle relationships in cultured 3T3-L1 preadipocytes.


